SCHEMBL710198

SCHEMBL710198

CS(=O)(=O)c1cccc(CCl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.48
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TSHR P16473 1/20 0.43
ADRA1D P25100 1/20 0.43
NPC1 O15118 1/20 0.42
TNF P01375 1/20 0.42
RAB9A P51151 1/20 0.42
NOD1 Q9Y239 1/20 0.42
GLA P06280 1/20 0.42
SLC6A4 P31645 1/20 0.41
GRM2 Q14416 2/20 0.41
GRM3 Q14832 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
LOX P28300 1/20 0.41
LOXL2 Q9Y4K0 1/20 0.41
NR1H2 P55055 1/20 0.40
NR1H3 Q13133 1/20 0.40
HTR6 P50406 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30661269 1.00 DRD2 (0.48) DRD2ALDH1A1GAAHSD17B10TSHR
SCHEMBL5232319 0.85 DRD2 (0.46) DRD2ALDH1A1GAAHSD17B10ADRA1D
SCHEMBL8233359 0.82 ALDH1A1 (0.47) DRD2ALDH1A1GAAHSD17B10NPC1
SCHEMBL7054313 0.82 ALDH1A1 (0.47) DRD2ALDH1A1GAAHSD17B10ADRA1D
SCHEMBL1598016 0.82 ALDH1A1 (0.48) DRD2ALDH1A1HSD17B10TSHRNPC1
SCHEMBL25290560 0.81 DRD2 (0.46) DRD2ALDH1A1GAAHSD17B10ADRA1D
SCHEMBL29593031 0.81 DRD2 (0.46) DRD2ALDH1A1GAAHSD17B10ADRA1D
SCHEMBL21753331 0.80 NR1H2 (0.51) LOXL2NR1H2NR1H3
SCHEMBL1127911 0.80 HTR6 (0.51) DRD2ALDH1A1GAAHSD17B10GRM2
SCHEMBL4313800 0.80 TSHR (0.52) ALDH1A1HSD17B10TSHRNPC1TNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117043163-A Pyrrolopyrimidine or pyrrolopyridine derivative and medical application thereof 希格生科(深圳)有限公司 2023-11-10 CN disclosed
WO-2023036252-A1 PYRROLOPYRIMIDINE OR PYRROLOPYRIDINE DERIVATIVE AND MEDICAL USE THEREOF 希格生科(深圳)有限公司 2023-03-16 WO disclosed
US-11584755-B2 Dihydrothieno[3,2-b]pyridine compounds IDEAYA BIOSCIENCES, INC. (US) 2023-02-21 US disclosed
CN-112028870-B Compound with benzyloxy aromatic ring structure, preparation method and application thereof 中国科学院上海药物研究所 2021-11-05 CN disclosed
WO-2020244518-A1 COMPOUND WITH BENZYLOXY AROMATIC RING STRUCTURE, PREPARATION METHOD AND USE THEREOF 中国科学院上海药物研究所 2020-12-10 WO disclosed
WO-2020244518-A1 COMPOUND WITH BENZYLOXY AROMATIC RING STRUCTURE, PREPARATION METHOD AND USE THEREOF 中国科学院上海药物研究所 2020-12-10 WO disclosed
CN-112028870-A Compound with benzyloxy aromatic ring structure, preparation method and application thereof 中国科学院上海药物研究所 2020-12-04 CN disclosed
CN-106536515-B Compound as immunomodulator 百时美施贵宝公司 2019-08-16 CN disclosed
WO-2019067442-A1 DIHYDROTHIENO[3,2-b]PYRIDINE COMPOUNDS IDEAYA BIOSCIENCES, INC. (US) 2019-04-04 WO disclosed
EP-3131876-B1 COMPOUNDS USEFUL AS IMMUNOMODULATORS BRISTOL MYERS SQUIBB CO (US) 2018-11-07 EP disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20060079685-A1 Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives NOVARTIS AG (CH) 2006-04-13 US disclosed
EP-1585521-A2 DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE Novartis AG (CH) 2005-10-19 EP disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
CN-1646125-A Substituted pyridones as modulators of P38MAP kinase PHARMACIA CORP (US) 2005-07-27 CN disclosed
WO-2005018557-A2 SUBSTITUTED PYRIDINONES PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed
EP-1490064-A1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE Pharmacia Corporation (US) 2004-12-29 EP disclosed
WO-2004056365-A2 DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE NOVARTIS AG (CH) 2004-07-08 WO disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed
WO-2003068230-A1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORPORATION (US) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079685-A1 Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives PTH1R, PTMS, CYP24A1 DRD2 2269/4885ALDH1A1 3159/4885GAA 1418/4885
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 DRD2 2625/4885ALDH1A1 787/4885GAA 2281/4885
US-11584755-B2 Dihydrothieno[3,2-b]pyridine compounds DHFR, CYC1, CYCS DRD2 2560/4885ALDH1A1 700/4885GAA 2336/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 DRD2 2177/4885ALDH1A1 741/4885GAA 2368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.